Merck & Company Inc (MRK)vsProMIS Neurosciences Inc. (PMN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
PMN
ProMIS Neurosciences Inc.
$13.56
+1.19%
HEALTHCARE · Cap: $121.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 880542215% more annual revenue ($66.57B vs $7,560). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
PMN
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for PMN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PMN
The strongest argument for PMN centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PMN
The primary concerns for PMN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →ProMIS Neurosciences Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Utilizing its proprietary protein engineering platform, ProMIS specializes in the identification and targeting of misfolded proteins associated with these diseases, which enhances the safety and efficacy of its drug candidates. The company boasts a robust and diverse pipeline of candidates in various stages of development, positioning it favorably to address significant unmet medical needs in the biopharmaceutical arena, making it a compelling investment opportunity for institutional investors seeking growth in the healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?